Inhibition of membrane redox activity by rhein and adriamycin in human glioma cells

Anticancer Drugs. 1992 Dec;3(6):615-21. doi: 10.1097/00001813-199212000-00009.

Abstract

The effect of the combination of adriamycin (ADM) with the anti-inflammatory drug rhein (RH) on the membrane redox activity in human glioma cells was investigated. RH, although less effective than ADM, inhibits ferricyanide reduction by human glioma cells in a dose-dependent manner as well as ferricyanide-induced proton release. The inhibition of the plasma membrane redox system might represent a further mechanism by which RH, other than ATP depletion, affects cell survival. The analysis of the interaction between ADM and RH, performed with the isobolar method, demonstrates a strong synergic response, probably due to an effect on different sites of action. The synergism of the ADM-RH association allows us to achieve a pre-established extent of inhibition with ADM concentrations much lower than with ADM alone. RH might, therefore, represent a very useful tool to improve the therapeutic index of ADM and to lower its general toxicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anthraquinones / pharmacology*
  • Cell Membrane / drug effects
  • Cell Membrane / metabolism
  • Cell Survival / drug effects
  • Doxorubicin / pharmacology*
  • Electron Transport / drug effects
  • Ferricyanides / chemistry
  • Glioblastoma / metabolism*
  • Glioblastoma / pathology
  • Humans
  • NADH, NADPH Oxidoreductases / antagonists & inhibitors*
  • Oxidation-Reduction
  • Tumor Cells, Cultured / drug effects

Substances

  • Anthraquinones
  • Ferricyanides
  • hexacyanoferrate III
  • Doxorubicin
  • NADH, NADPH Oxidoreductases
  • rhein